Advances in Heart Failure - Is It Time to Redefine Patient Selection for Sodium-Glucose Co-transporter 2 Inhibitors?
This educational symposium was originally broadcast as part of the ESC 2020 Digital Congress.
The programme focuses on summarising recent data on SGLT2 inhibitors showing reductions in CV risk, HF hospitalisations and mortality, as well as improved quality-of-life. The expert panel also discuss how these agents should be introduced into clinical practice and contemporary heart failure guidelines for both diabetics and non-diabetics.
Learning Objectives
- Discuss Current SGLT2 Data and Guideline Recommendations for Utilization in Heart Failure
- Evaluate Emerging Data on the Treatment of Heart Failure with SGLT2 Inhibitors
- Understand the Implications of Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors
More from this programme
Part 1
SGLT2s as a Heart Failure Drug – How Did We Get Here?
Part 2
Emerging Data SGLT2 Inhibitors in Heart Failure
Part 3
Guidelines and Practice Implications
Part 4
Q&A Discussion
| 1 session | |
| Q&A Discussion | Watch now |
Part 5
Follow-up Peer-to Peer Discussion
| 1 session | |
| Follow-up Peer-to Peer Discussion | Watch now |
Faculty Biographies
Andrew JS Coats
Professor of Cardiology and Scientific Director
Professor Andrew Coats was born in Melbourne, Australia. He studied at St Catherine’s College, Oxford, where he earned a B.A. in Physiological Sciences with First-Class Honours, and then completed his medical degree (M.B. B.Chir.) at Clare College, Cambridge. He later obtained higher doctorates (D.M. and D.Sc.) in recognition of his substantial contributions to cardiovascular medicine, and he also completed an MBA at the London Business School. Professor Coats serves as Editor-in-Chief of the Cardiac Failure Review journal.
Career Overview
Andrew Coats is an internationally renowned academic cardiologist, inventor, and university leader with a career spanning more than three decades. He is currently the Scientific Director and CEO of the Heart Research Institute in Sydney, Australia. He also serves as Dean of the Royal Australasian College of Physicians, Affiliate Professor at Deakin University, and Emeritus Professor of Medicine at Monash University.
…
Faiez Zannad
Professor Emeritus; Founder and Chairman of CVCT Société Civile
Prof Faiez Zannad was born in Monastir, Tunisia in 1951 and later moved to pursue his medical education and research in Europe. He trained in cardiology and pharmacology across institutions in France and the United Kingdom, including Nancy, Lyon, and Oxford. Over the course of his career, he has lived and worked primarily in Nancy, France, where he has held clinical, academic, and research leadership roles in cardiovascular medicine and therapeutics.
Academic History
Prof Zannad earned his MD in cardiology from the Faculté de Médecine de Nancy and further trained as a research fellow in clinical pharmacology at the Medical Research Council in Oxford. He later received a PhD in cardiovascular clinical pharmacology from the University of Lyon. During his academic training, he focused on cardiovascular pharmacology, physiology, and therapeutic innovation, laying the foundation for his lifelong work in heart failure and hypertension research.
Following…